Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05458297
Title A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination With Nemtabrutinib (MK-1026) in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | ESP | DEU | CAN

No variant requirements are available.